Seeking Alpha
10 Jun 2026, 19:32 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Celcuity has a pending PDUFA date for its lead candidate, gedatolisib, in a Phase III study for second-line HR+/HER2-negative advanced breast cancer. — An imminent FDA decision on a Phase III lead candidate is a binary event that typically causes significant price volatility for small-cap biotech firms.
+0.80The FDA has granted priority review for the drug's application in the wild-type population. — Priority review accelerates the timeline to potential commercialization, increasing the net present value of the asset.
+0.40Celcuity claims gedatolisib demonstrates superior efficacy and better tolerability compared to existing approved drugs in the PI3K/AKT/mTOR pathway class. — Competitive superiority in a challenging oncogenic pathway suggests a stronger potential market share upon approval.
+0.30Which stocks this story touches
Continue reading
6 related stories
Top 2 movers · tap to explore
The company reports 'unprecedented results' in a Phase III study and has received FDA priority review for its lead candidate.
Goldman Sachs is mentioned only as the host of the healthcare conference.
Go deeper
You just saw which tickers this one story hits. A free account turns that into a standing screen: the movers delivered on schedule, before the chart catches up.
On this page · free
In the platform
Free account, 30 seconds. No credit card. Covers all 10 tickers this story moves.
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Screener bridge
GS showed up in this week’s NIS Momentum screen.
Get the full NIS Momentum results every Friday at 4PM ET — free via email or Telegram.
Seeking Alpha
1h ago
